$ProQR Therapeutics NV(PRQR)$The consensus EPS estimate for the current year has increased 14.6% over the last 30 days. This means that the Wall Street analysts covering PRQR are majorly in agreement about the company's potential to report better earnings than what they predicted earlier.
If this is not enough, you should note that PRQR currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises. And stocks carrying a Zacks Rank #1 or 2 usually outperform the market. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Moreover, the Zacks Rank has proven to be an excellent timing indicator, helping investors identify precisely when a company's prospects are beginning to improve. So, for the shares of ProQR, a Zacks Rank of 2 is a more conclusive fundamental indication of a potential turnaround.
Comments